Skip to main content
Caplight Logo









Vascudyne

Vascudyne

Private
Saint Paul, MinnesotaHealthcare & Life Scienceshttps://vascudyne.com/

Last Round

Grant

Jun 1, 2025

Total Funding Raised

$14M

Company Overview

Vascudyne is a biotechnology company that develops a bioengineered tissue platform designed to create implantable blood vessels and heart valves for cardiovascular care.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicinetissue engineeringheart valve replacementacellular tissue graftvascular graftoff-the-shelf implanthemodialysis access graftbiological implantregenerative implantpediatric heart valveimplantable scaffoldclinical-stage medtechsoft tissue repairClass III medical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vascudyne Comparables

Compare Vascudyne with similar companies based on industry and business-model similarity.

Vascudyne comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xeltis
87%
Anova Biomedical
81%
VeriGraft
81%

Vascudyne Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2025
Series ADec 2, 2021

Key People

Founding team and executive leadership

Zeeshan Syedain

Chief Executive Officer, Chief Science Officer

Executive Team

Vascudyne Investors

Notable investors and investment history

Vascudyne investors
InvestorRounds
Congressionally Directed Medical Research ProgramsGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors increased 83% MoM.

  • Jun 1, 2025

    $4M grant received from Congressionally Directed Medical Research Programs.

Vascudyne Filings

Explore SEC and related filing metadata, where available.

Vascudyne filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vascudyne's valuation, stock price, and market status.

Is Vascudyne a public or private company?

Vascudyne is a private company.

What is the current stock price of Vascudyne?

Vascudyne is a private company with no public stock price. No recent secondary market data is available.

How much is Vascudyne worth (valuation)?

Valuation information for Vascudyne is not publicly available.

Can I buy Vascudyne stock?

Vascudyne shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vascudyne's last funding round?

Vascudyne's most recent funding round was Grant on June 1, 2025.

Who are the main investors in Vascudyne?

Key investors in Vascudyne include Congressionally Directed Medical Research Programs.

Will Vascudyne IPO soon?

No public IPO plans have been announced for Vascudyne.

How can I track Vascudyne secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vascudyne's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSaint Paul, Minnesota
Employee Range13
Year Founded2014
Last FundingJun 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?